LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SABS
SAB Biotherapeutics, Inc.
There isn't enough reported data to score SABS yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SABS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SABS's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SABS PE Valuation
SABS has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SABS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect SABS's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus SABS down 150%.
SABS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.09 | +$3.10 |
| Q2 2025 | -$4.00 | +$2.07 |
| Q1 2025 | -$3.70 | +$2.98 |
| Q4 2024 | -$3.68 | +$3.96 |
| Q3 2024 | -$6.19 | -$0.46 |
| Q2 2024 | -$6.07 | +$0.26 |
| Q1 2024 | -$6.68 | -$0.65 |
| Q4 2023 | -$7.64 | -$3.31 |
SABS is still losing money, but far less than before: $3.09 per share over the past year, against $9.10 at its worst in early 2022.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus down 62% for SABS.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
SABS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $114.7K | -62% |
| Q2 2024 | $263.1K | +208% |
| Q1 2024 | $944.6K | +63% |
| Q4 2023 | $305K | -86% |
| Q3 2023 | $1.3M | -65% |
| Q2 2023 | $85.5K | -99% |
| Q1 2023 | $581.1K | -95% |
| Q4 2022 | $2.2M | -80% |
SABS's revenue has slid since its 2022 peak: $114,698 last quarter, down 62% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -8726% | -2538 points |
| Q2 2024 | -3877% | +3696 points |
| Q1 2024 | -1206% | +68 points |
| Q4 2023 | -6188% | -5824 points |
| Q3 2023 | -420% | -203 points |
| Q2 2023 | -7573% | -7470 points |
| Q1 2023 | -1274% | -1217 points |
| Q4 2022 | -364% | -297 points |
SABS's operating margin was −8726% last quarter, down 8306 points from the same quarter a year ago, near the bottom of its range since 2021.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with SABS at down 97%.
SABS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$9.6M | +$3.9M |
| Q3 2024 | -$6.4M | -$1.1M |
| Q2 2024 | -$7.8M | -$2.8M |
| Q1 2024 | -$10.9M | -$9.3M |
| Q4 2023 | -$13.5M | -$11.8M |
| Q3 2023 | -$5.3M | +$3M |
| Q2 2023 | -$4.9M | +$900.1K |
| Q1 2023 | -$1.6M | +$10M |
SABS has burned cash in almost every quarter: −$51M over the past year, against −$39M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SABS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SABS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +13.5M shares |
| 1 year | +903% | +83.9M shares |
| 3 years | +1750% | +88.2M shares |
| 5 years | +37195% | +93M shares |
SABS has 93M diluted shares, up 903% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SABS Net Leverage
SABS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SABS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.1 | Neutral |
| Stochastic | 46.0 | Neutral |
SABS's weekly RSI is 45 (neutral) and its Stochastic is 46 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SABS PE vs Healthcare Sector
| Metric | SABS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SABS has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SABS on trend strength, trading above more of its moving averages.
SABS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.01 | 2.3% above |
| 20 week MA | $3.41 | 9.7% below |
| 50 week MA | $3.66 | 16% below |
| 100 week MA | $3.02 | 2% above |
| 200 week MA | $4.35 | 29% below |
SABS's trend is mixed: it's above two of its five weekly moving averages, and 29% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SABS on returns for 2026, with the stronger performance.
SABS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $102.1 | $87.5 | -14% |
| 2022 | $87.5 | $6.90 | -92% |
| 2023 | $6.90 | $6.88 | -0.3% |
| 2024 | $6.88 | $4.18 | -39% |
| 2025 | $4.18 | $3.78 | -9.6% |
| 2026 YTD | $3.78 | $3.08 | -19% |
SABS has finished every year since 2021 lower, and it's down 19% so far in 2026.